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ABSTRACT
The outcome of organ transplantation is largely dictated by selection of a well-matched 
donor, which results in less chance of graft rejection. An allogeneic immune response is the 
main immunological barrier for successful organ transplantation. Donor and recipient human 
leukocyte antigen (HLA) mismatching diminishes outcomes after solid organ transplantation. 
The current evaluation of HLA incompatibility does not provide information on the 
immunogenicity of individual HLA mismatches and impact of non-HLA-related alloantigens, 
especially in vivo. Here we demonstrate a new method for analysis of alloimmune 
responsiveness between donor and recipient in vivo by introducing a humanized mouse 
model. Using molecular, cellular, and genomic analyses, we demonstrated that a recipient’s 
personalized humanized mouse provided the most sensitive assessment of allogeneic 
responsiveness to potential donors. In our study, HLA typing provided a better recipient-
donor match for one donor among two related donors. In contrast, assessment of an 
allogeneic response by mixed lymphocyte reaction (MLR) was indistinguishable between 
these donors. We determined that, in the recipient’s humanized mouse model, the donor 
selected by HLA typing induced the strongest allogeneic response with markedly increased 
allograft rejection markers, including activated cytotoxic Granzyme B-expressing CD8+ T 
cells. Moreover, the same donor induced stronger upregulation of genes involved in the 
allograft rejection pathway as determined by transcriptome analysis of isolated human 
CD45+cells. Thus, the humanized mouse model determined the lowest degree of recipient-
donor alloimmune response, allowing for better selection of donor and minimized 
immunological risk of allograft rejection in organ transplantation. In addition, this approach 
could be used to evaluate the level of alloresponse in allogeneic cell-based therapies that 
include cell products derived from pluripotent embryonic stem cells or adult stem cells, both 




1.) Hu-PBMC-NSG mouse show efficient engraftment with up to 60% of the engrafted CD8+ T cells being naïve T 
cell (TN) phenotype being CD62L+CD25-
2.) The NSG-PBMC model showed a selective immune CD8+ T cell-based response on the UD allogeneic stimuli 
while at the same time exhibited a tempered/controlled feedback to the RD challenge
3.) The NSG-PBMC model showed an immune transcriptional profile
4.) MLR expresses minimal allogeneic response both cellular and transcriptional
5.) The Hu-PBMC-NSG model is significantly more sensitive than MLR
NSG-PBMC humanized mouse model was able to identify the related donor exhibiting minimal allogeneic response 
to the recipient. This model is significantly more immunologically sensitive than conventional MLR and HLA typing for 




Solid organ transplantation has been a life-saving procedure for thousands of patients 
worldwide. Recent advances on improving donor-screening diagnostics have aimed at 
identification of the most compatible donor for the transplant recipient to maximize allograft 
survival. Current standards of donor selection rely on HLA typing and in vitro MLR, which 
does not take into account the in vivo environment and recipient’s adaptive immune 
response. Humanized mouse models are an appealing alternative that permits personalized 
investigation of the immunocompatibility of potential donor tissues for the recipient human 
immune system without putting patients at risk. By utilizing genomics, molecular and cellular 
analyses of allogeneic immune response we analyze the efficiency of our novel humanized 
mouse model to assess the donor-recipient compatibility and determined that it to be 
significantly more sensitive than conventional screening methods.
HLA typing and MLR for histocompatibility. Special strain of immunodeficient mice, NSG 
mice, subjected to irradiation (2Gy) and i.v injection of 8×10 peripheral blood mononuclear 
cells (PBMCs) from transplant recipient. For allogeneic immune response, humanized 
mouse received 3×10 PBMCs from unrelated donors(UD) or related donors(RD). Whole 
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Figure 3. Representative flow cytometry color plots depict gating strategy for CD25+ Granzyme B and Perforin-expressing activated 
cytotoxic hCD8+ T cells in spleen of the humanized mouse for the Autologous, Related Donor (RD), and Unrelated Donor (UD) 
challenge groups. Histogram shows expression of pro-inflammatory cytokines IL-2 (red line) and IFN-γ (blue line) amongst these  
cytotoxic hCD8+T cells.
Figure 2. Flow cytometry dot plots depict phenotype of the engrafted hCD45+ cells in the humanized mouse with gating for hCD3+, 
hCD4+, and hCD8+ T cell populations. Characterization of hCD4 and hCD8+ T cells was expanded showing their respective CD62L 
and CD25 expression. Graphical summary depicts frequency (%) of hCD4 and hCD8+ T cells as well as percent of CD62L+CD25-
and CD62L-CD25+ populations. N=5 mice per group. Data presented as mean ± SD. ***p <0.001, ****p<0.0001.
Figure 4. Human Gene 2.0 ST array was used to plot a heat map representing differential gene expression in hCD3+ T cells of the 
allogeneic RD and UD challenges for the MLR and the humanized mouse models. Hierarchical clustering was used to segregate 
individual gene expression in each group into reduced expression (blue) and over-expression (red) conditions.
Immunological graft rejection originates from alloimmune T cells derived from the host immune system. The 
host alloimmune T cell response against donor-derived antigens such as HLA are much stronger in comparison 
to classical immune responses against pathogen or self. This is due to the highly polymorphic nature of HLAs 
combined with the presence of multiple HLA loci (HLA-A, B-class I antigens; HLA-DR, DQ, DP- class II 
antigens). A diverse mismatch across the HLA alloantigens between the recipient and donor can elicit a robust 
allogeneic immune response. These allospecific T cells of the host immune system can form activated cytotoxic 
Granzyme B-expressing CD8+ T cells that are primarily responsible for graft tissue destruction and transplant 
failure. Therefore, selection of the most immunocompatible donor for the recipient with the least amount of HLA 
mismatches can maximize graft survival and reduce dependency on immunosuppressive treatments. In this 
scenario, a well-matched related donor is the perfect candidate, allowing adequate time for investigating the 
level of histocompatibility with the recipient. HLA typing and MLR are the long-time clinical standards for the 
assessment of donor-recipient immunocompatibility in organ transplantation. Various studies have established 
that an increased number of matched antigens and decreased number of mismatched antigens lead to 
improved graft survival. However, HLA typing results are often confounded by the varying immunogenicity of the 
different HLA loci. HLA-DR mismatches are known to contribute heavily to graft rejection, and HLA-A and B 
matches are also crucial for graft acceptance. Meanwhile, HLA-DQ mismatch has no clinical significance unless 
it is compounded by the presence of a DR mismatch; DP mismatches only become relevant during regraft 
scenarios. Current donor organ allocation strategies consider mismatches at HLA-A, B, and DR to be equally 
important. However, mounting evidence suggests that each HLA mismatch contributes differently to graft 
survival; some HLA mismatches look more permissible than others. Benefits of dependence on HLA matching 
are further diluted by other factors such as age; a younger donor age can compensate for the impact of HLA 
mismatches. However, HLA typing does not consider the impact of non-HLA-related alloantigens. Growing 
evidence suggests that as much as 38% of kidney allograft rejections are due to these non-HLA-related 
alloantigens in comparison to 18 % caused by HLA mismatches. Thus, there is a need for additional methods to 
assess immunocompatibility between recipient and donor. The most common and routinely used solution is 
MLR. CFSE-based MLR assays enabled the phenotypic characterization of alloimmune T cells developed by 
the recipient on stimulation by donor immune cells. However, the correlation between clinical outcomes and in 
vitro functional MLR assays has been low due to the inherent inability of in vitro assays to replicate the in vivo 
physiological environment. For example, unresponsive donor reactive cells commonly seen in MLR may arise 
due to deletion or anergy, a phenomenon that is indistinguishable in an in vitro setting. 
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OBSERVATIONS
Humanized Mouse Model for Organ Transplantation
Figure 1. For the development of a humanized mouse model, we used NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice from The Jackson 
Laboratory. NSG mice (5 to 12 weeks old) were given a single intravenous lateral tail injection of different amounts of human
peripheral blood mononuclear cells (PBMCs) from healthy volunteers (recipients).
